InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
ConwayTwitty Free
04/10/24 10:49 AM
profile icon
Monksdream PremiumMember
01/20/24 4:36 PM
profile icon
make it happen Free
11/01/23 10:26 AM
profile icon
make it happen Free
10/27/23 2:07 PM
profile icon
bikaver Free
10/19/23 4:49 PM
profile icon
LowFloatLopes Free
09/29/23 2:07 PM
profile icon
Whalatane PremiumMember
09/27/23 8:09 PM
profile icon
MiamiGent PremiumMember
09/27/23 3:28 PM
profile icon
MiamiGent PremiumMember
09/27/23 3:23 PM
profile icon
Whalatane PremiumMember
09/27/23 2:21 PM
profile icon
MiamiGent PremiumMember
09/27/23 12:30 PM
profile icon
MiamiGent PremiumMember
09/27/23 11:42 AM
profile icon
MiamiGent PremiumMember
09/27/23 11:10 AM
profile icon
seko19822 Free
09/27/23 2:04 AM
profile icon
SriMaharaj Free
09/26/23 6:40 PM
profile icon
bikaver Free
09/26/23 4:15 PM
Bearish
Bearish
profile icon
Whalatane PremiumMember
09/26/23 3:30 PM
profile icon
BoilerRoom Free
09/26/23 2:26 PM
profile icon
TheFinalCD PremiumMember
09/26/23 1:54 PM
profile icon
TIMGZ Free
09/26/23 1:50 PM
profile icon
TIMGZ Free
09/26/23 1:49 PM
profile icon
TheFinalCD PremiumMember
09/26/23 1:42 PM
profile icon
Whalatane PremiumMember
09/26/23 1:22 PM
profile icon
Whalatane PremiumMember
09/26/23 10:48 AM
profile icon
make it happen Free
09/26/23 10:39 AM
profile icon
Whalatane PremiumMember
09/26/23 10:30 AM
profile icon
make it happen Free
09/26/23 10:25 AM
profile icon
Whalatane PremiumMember
09/26/23 10:16 AM
profile icon
make it happen Free
09/26/23 10:02 AM
profile icon
make it happen Free
09/26/23 9:48 AM
profile icon
Whalatane PremiumMember
09/26/23 9:44 AM
profile icon
Triple nickle Free
09/26/23 9:38 AM
profile icon
LowFloatLopes Free
09/26/23 9:37 AM
profile icon
TheFinalCD PremiumMember
09/26/23 9:36 AM
profile icon
INV4 PremiumMember
09/26/23 9:21 AM
profile icon
BeamMeUpScotty Free
09/26/23 9:19 AM
profile icon
LowFloatLopes Free
09/26/23 9:18 AM
profile icon
BoilerRoom Free
09/26/23 9:06 AM
profile icon
TheFinalCD PremiumMember
09/26/23 9:06 AM
profile icon
TrendTrade2016 PremiumMember
09/26/23 9:01 AM
profile icon
make it happen Free
09/26/23 8:59 AM
profile icon
make it happen Free
09/26/23 8:58 AM

Soleno Therapeutics Inc (SLNO) RSS Feed

Followers
32
Posters
99
Posts (Today)
0
Posts (Total)
300
Created
02/19/15
Type
Free
Moderators
Soleno (SLNO) is a new formed company  through the merger between Capnia and the private Essentials (merger completed in march 2017) . SLNO has a potential BLOCKBUSTER in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments  . This unknown low float stock which has a terrible low valuation of $16 million could be the next SRPT the stock should be valued above $100 million right now for their Phase 3 Program and in the Billions if the outcome of the Phase 3 trial is positive which expected by next year .GL

Soleno therapeutics (SLNO)

Market Cap $16 Million
Cash: $8 Million
Price $0.35

Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)


$2.3 BILLION Market Potential for the Prader Willi Syndrome no approved treatments for this Indication


Maxim Group set a $5.00 target price on Capnia, Inc. (NASDAQ:SLNO) in a research note issued to investors on Wednesday, July 5th. The firm currently has a buy rating on the stock.

https://www.thecerbatgem.com/2017/08/04/maxim-group-analysts-give-capnia-inc-slno-a-5-00-price-target-updated-updated-updated.html



Initiating Coverage June 26, 2017
http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

Market Opportunity for PWS is Substantial.

While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.


VERY Strong Insiders & Institutional ownership :

Vivo Ventures LLC     16 012 808   
Forward Ventures Services LLC     7 251 728   
Technology Partners     7 050 691   
Aspire Capital Partners LLC     2 791 666   
Ernest Mario, PhD     1 844 328   
Oppenheim Asset Management Services SARL     574 853   
Medical Strategy GmbH     503 305   
Palo Alto Investors LLC     423 738   
Sabby Capital LLC     248 067   
The Bollard Group LLC  192 217   



Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post